Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells

doi:10.4251/wjgo.v17.i7.106723

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-3)

Sum=0

Jul 15, 2025 (publication date) through Jul 14, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Jul 15, 2025; 17(7): 106723
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.106723

Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells

Meng-Yan Chen, Chen Wang, Yu-Gang Wang, Min Shi

Meng-Yan Chen, Chen Wang, Yu-Gang Wang, Min Shi, Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China

Co-first authors: Meng-Yan Chen and Chen Wang.

Co-corresponding authors: Yu-Gang Wang and Min Shi.

Author contributions: Shi M and Wang YG conceptualized the theme and structure of this review; Chen MY was the primary contributor to the manuscript writing; Wang C provided guidance and revised the initial draft; All authors have read and approved the final manuscript.

Supported by the Natural Science Foundation of the Science and Technology Commission of Shanghai Municipality, China, No. 23ZR1458300; Key Discipline Project of Shanghai Municipal Health System, China, No. 2024ZDXK0004; Doctoral Innovation Talent Base Project for Diagnosis and Treatment of Chronic Liver Diseases, China, No. RCJD2021B02; and Pujiang Project of Shanghai Magnolia Talent Plan, China, No. 24PJD098.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Min Shi, MD, Chief Physician, Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Changning District, Shanghai 200336, China. sm1790@shtrhospital.com

Received: March 6, 2025
Revised: April 7, 2025
Accepted: May 29, 2025
Published online: July 15, 2025
Processing time: 130 Days and 17.6 Hours

Core Tip

Core Tip: This review discusses adoptive cell therapy approaches for colorectal cancer (CRC), emphasizing chimeric antigen receptor (CAR) T cell therapy. Despite its success in hematological malignancies, CAR-T therapy faces challenges in solid tumors like CRC, including antigen heterogeneity, tumor microenvironment immunosuppression, and on-target off-tumor toxicity. In this review, we explore combinatorial strategies, such as immune checkpoint inhibitors and CRISPR/Cas9 gene editing, to overcome these challenges and enhance CAR-T cell specificity, resistance to immunosuppressive signals, and in vivo functionality.